Aristotelis Bamias, MD, on Atezolizumab Monotherapy vs Chemotherapy for Urothelial Carcinoma

Posted: Wednesday, March 8, 2023

Aristotelis Bamias, MD, of the National and Kapodistrian University of Athens, discusses the ramifications of final overall survival results from the IMvigor130 study, which suggest that atezolizumab monotherapy continues to show better tolerability vs chemotherapy for patients with untreated locally advanced or metastatic urothelial carcinoma. Dr. Bamias addresses the question of whether these data are likely to be practice-changing.

---